What is HC Wainwright's Estimate for ARQT Q1 Earnings?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Arcutis Biotherapeutics in a research report issued to clients and investors on Wednesday, May 7th. HC Wainwright analyst D. Tsao expects that the company will post earnings per share of ($0.15) for the quarter. HC Wainwright has a "Buy" rating and a $19.00 price objective on the stock. The consensus estimate for Arcutis Biotherapeutics' current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics' Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.20 EPS, FY2027 earnings at $1.18 EPS, FY2028 earnings at $1.89 EPS and FY2029 earnings at $2.43 EPS.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.01. The company had revenue of $65.85 million for the quarter, compared to analyst estimates of $64.80 million. Arcutis Biotherapeutics had a negative return on equity of 119.11% and a negative net margin of 140.97%.

Several other brokerages also recently issued reports on ARQT. Mizuho boosted their target price on shares of Arcutis Biotherapeutics from $20.00 to $21.00 and gave the company an "outperform" rating in a research note on Wednesday, February 26th. Needham & Company LLC restated a "buy" rating and issued a $20.00 price objective on shares of Arcutis Biotherapeutics in a research report on Wednesday, April 9th. The Goldman Sachs Group lifted their price target on shares of Arcutis Biotherapeutics from $13.00 to $15.00 and gave the stock a "neutral" rating in a research report on Thursday, February 27th. Guggenheim reiterated a "buy" rating on shares of Arcutis Biotherapeutics in a research note on Thursday, April 3rd. Finally, Jefferies Financial Group increased their target price on shares of Arcutis Biotherapeutics from $16.00 to $19.00 and gave the stock a "buy" rating in a research report on Tuesday, March 11th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $18.80.

Arcutis Biotherapeutics Stock Performance

Shares of ARQT traded down $0.58 during mid-day trading on Thursday, reaching $13.81. 1,301,880 shares of the company's stock traded hands, compared to its average volume of 2,378,190. The business's 50-day moving average price is $14.77 and its 200-day moving average price is $13.31. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.38 and a current ratio of 2.46. The stock has a market capitalization of $1.65 billion, a P/E ratio of -7.72 and a beta of 1.87. Arcutis Biotherapeutics has a 12 month low of $6.99 and a 12 month high of $17.75.

Institutional Trading of Arcutis Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Barclays PLC boosted its holdings in Arcutis Biotherapeutics by 45.8% during the 3rd quarter. Barclays PLC now owns 253,392 shares of the company's stock valued at $2,356,000 after acquiring an additional 79,579 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Arcutis Biotherapeutics by 0.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,296,911 shares of the company's stock valued at $12,061,000 after acquiring an additional 11,833 shares during the last quarter. LVW Advisors LLC purchased a new position in Arcutis Biotherapeutics in the 4th quarter worth approximately $166,000. SG Americas Securities LLC increased its position in shares of Arcutis Biotherapeutics by 25.4% in the 4th quarter. SG Americas Securities LLC now owns 48,087 shares of the company's stock worth $670,000 after purchasing an additional 9,754 shares during the last quarter. Finally, Zweig DiMenna Associates LLC bought a new position in Arcutis Biotherapeutics during the fourth quarter worth $578,000.

Insider Activity

In related news, insider Todd Franklin Watanabe sold 1,500 shares of Arcutis Biotherapeutics stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $17.52, for a total transaction of $26,280.00. Following the completion of the transaction, the insider now directly owns 927,414 shares of the company's stock, valued at approximately $16,248,293.28. The trade was a 0.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Howard G. Welgus sold 10,000 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $13.00, for a total transaction of $130,000.00. Following the completion of the sale, the director now directly owns 131,944 shares of the company's stock, valued at $1,715,272. The trade was a 7.05% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,662 shares of company stock worth $527,326. 9.50% of the stock is currently owned by insiders.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.